<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25906" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, NMDA Receptor</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jewett</surname>
            <given-names>Benjamin E.</given-names>
          </name>
          <aff>Quillen College of Medicine, East Tennessee State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thapa</surname>
            <given-names>Bicky</given-names>
          </name>
          <aff>Cleveland Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Benjamin Jewett declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bicky Thapa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25906.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The N-methyl-D-aspartate (NMDA) receptor is a glutamate receptor, the human brain's primary excitatory neurotransmitter. It plays an integral role in synaptic plasticity, a neuronal mechanism believed to be the basis of memory formation. NMDA receptors also appear to be involved in a process called excitotoxicity. Excitotoxicity may play a role in the pathophysiology of a variety of diseases, such as epilepsy or Alzheimer disease. Many drugs inhibit NMDA receptors, including ketamine and phencyclidine,&#x000a0;2 common drugs of abuse.</p>
      </sec>
      <sec id="article-25906.s2" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>Glutamate is the predominant excitatory neurotransmitter in the central nervous system. It binds to several receptors, such as the AMPA, NMDA, and kainate receptors, each named after the laboratory molecule that selectively binds to them. These receptors often work in concert with one another in complex networks. The NMDA receptor is ionotropic&#x000a0;and controls a ligand-gated ion channel. It is particularly important because it is integral in long-term potentiation, synaptic plasticity, and memory formation.<xref ref-type="bibr" rid="article-25906.r1">[1]</xref></p>
        <p>There are multiple subtypes of NMDA receptors. Each receptor has&#x000a0;2 N1 subunits with either&#x000a0;2 N2 or&#x000a0;2 N3 subunits. The N1/N2 NMDA receptor complex is of primary physiological relevance. The receptor has several parts, including an extracellular ligand-binding domain and a transmembrane ion channel. When a ligand binds to the NMDA receptor, the ligand-binding domain closes like a clamshell. This closure leads to an opening of the transmembrane ion channel. The transmembrane ion channel is nonspecific for positively charged ions. However, due to the chemical properties of the channel and the concentrations of ions outside the cell, calcium ions often&#x000a0;pass through the channel.<xref ref-type="bibr" rid="article-25906.r2">[2]</xref>&#x000a0;</p>
        <p>Regulation of the transmembrane ion channel is complex and multifactorial, allowing for precise control of ion permeability in physiologic conditions. Disruption of this regulation can be lethal to the cell. For the ion channel to open, several things must happen simultaneously. First,&#x000a0;2 molecules of either glycine or serine&#x000a0;must bind to the NMDA receptor. Glycine binds to extrasynaptic receptors; serine&#x000a0;] binds to receptors within the synapse. Second,&#x000a0;2 molecules of glutamate must bind to the receptor. However, the channel may not open&#x000a0;even if it meets both. Magnesium and zinc bind to sites on the NMDA receptor and block the transmembrane ion channel. This blockage prevents calcium ions from entering. For the channel to be permeable to calcium, magnesium, or zinc, it must be dislodged from the cell by depolarization of the postsynaptic neuron. If another glutamate receptor, such as an AMPA receptor, is activated, it can depolarize the postsynaptic cell and dislodge magnesium or zinc, allowing the channel to open. In this way, the NMDA receptor serves as a&#x000a0;coincidence detector. The channel only opens if the postsynaptic cell depolarizes while glutamate enters the synapse. Additionally, this allows a graded response to stimuli.<xref ref-type="bibr" rid="article-25906.r3">[3]</xref>&#x000a0;</p>
        <p>Three possible responses can occur: short-term potentiation, long-term potentiation, and excitotoxicity.&#x000a0;A small depolarization of the postsynaptic cells only partially dislodges magnesium or zinc, allowing a small number of calcium ions to enter the cell. These calcium ions serve as second messengers, temporarily recruiting more AMPA receptors to the cell. This recruitment increases the chance of future depolarization. The effect of this change only lasts for a few hours at most, so this process is known as short-term potentiation. A large depolarization completely dislodges magnesium or zinc, allowing a large volume of calcium to enter the cell. This calcium can interact with transcription factors, encouraging the growth of the neuron. This&#x000a0;growth is known as long-term potentiation and is the mechanism behind synaptic plasticity, the brain's ability to "rewire" itself. These effects can last for years. An overwhelmingly prolonged depolarization allows unregulated passage of calcium into the cell, which is lethal to it, and this&#x000a0;effect is known as excitotoxicity.&#x000a0;This process&#x000a0;is known&#x000a0;to&#x000a0;occur in a multitude of neurological diseases.</p>
      </sec>
      <sec id="article-25906.s3" sec-type="Development">
        <title>Development</title>
        <p>NMDA receptors are integral to the development of the brain. They help in the maturation of various glutamatergic synapses. Knockout studies of different NMDA receptor subunits have demonstrated neurologic deficits in animal models, such as failure to develop orientation selectivity in the visual cortex. NMDA receptors are involved in the regulation of synaptic plasticity and thus impact the lifelong development of the brain. Much research remains to elucidate the precise mechanisms of the NMDA receptor on brain development.<xref ref-type="bibr" rid="article-25906.r4">[4]</xref></p>
      </sec>
      <sec id="article-25906.s4" sec-type="Organ Systems Involved">
        <title>Organ Systems Involved</title>
        <p>The NMDA receptor is integral to synaptic plasticity and can delicately control ion permeability into the cell. Therefore, it is unsurprising that it is virtually ubiquitous throughout the central nervous system. For example, roughly 80% of cortical neurons feature NMDA receptors. They preferentially express on pyramidal neurons. They are also present in astrocytes, glial cells traditionally thought to support neurons.<xref ref-type="bibr" rid="article-25906.r5">[5]</xref>&#x000a0;NMDA receptors are also present within the hippocampus, playing a crucial role in memory formation. NMDA receptors exist within the peripheral nervous system.<xref ref-type="bibr" rid="article-25906.r6">[6]</xref>&#x000a0;NMDA receptor subunits are also expressed in the kidney and cardiovascular system of the rat, though their purposes are unclear.<xref ref-type="bibr" rid="article-25906.r7">[7]</xref></p>
      </sec>
      <sec id="article-25906.s5" sec-type="Function">
        <title>Function</title>
        <p>NMDA receptors are involved in myriad functions within the central nervous system.<xref ref-type="bibr" rid="article-25906.r6">[6]</xref>&#x000a0;Because this receptor allows a graded response to stimuli and precise control over calcium entry into the cell, it impacts many central nervous system functions. A classic example of NMDA receptor functionality is the acquisition of new memories. This memory encoding occurs via the process of long-term potentiation.&#x000a0;The current belief is that the hippocampus is a critical brain area for this process.<xref ref-type="bibr" rid="article-25906.r8">[8]</xref></p>
      </sec>
      <sec id="article-25906.s6" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The NMDA receptor is involved in a variety of disease states, including:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Alzheimer disease:</italic> NMDA receptors become severely disordered in this disease, a progressive and debilitating neurodegenerative disorder of unclear etiology. While the precise mechanisms of this remain unclear, it is well known that memantine, an NMDA receptor uncompetitive antagonist, improves Alzheimer symptoms.<xref ref-type="bibr" rid="article-25906.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Huntington disease:</italic> This is a hereditary neurodegenerative disorder that also involves NMDA receptor-mediated excitotoxicity.<xref ref-type="bibr" rid="article-25906.r10">[10]</xref>&#x000a0;Memantine and amantadine, both NMDA receptor antagonists, reduce symptoms of Huntington disease.<xref ref-type="bibr" rid="article-25906.r11">[11]</xref><xref ref-type="bibr" rid="article-25906.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Epilepsy, stroke,&#x000a0;and traumatic brain injury:</italic>&#x000a0;These events involve calcium-mediated excitotoxicity. For example, in epilepsy, uncontrolled neuronal firing leads to excitotoxicity and permanent brain damage. It appears that similar processes occur in stroke and traumatic brain injury.<xref ref-type="bibr" rid="article-25906.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Major depressive disorder:&#x000a0;</italic>NMDA receptors may be involved in major depressive disorder, as ketamine, an NMDA receptor antagonist, has shown promise in its treatment.<xref ref-type="bibr" rid="article-25906.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Tinnitus:&#x000a0;</italic>NMDA receptors may be involved in the pathophysiology of tinnitus.<xref ref-type="bibr" rid="article-25906.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Anti-NMDA receptor encephalitis</italic>&#x000a0;is a rare, potentially lethal autoimmune encephalitis where autoantibodies are produced against the NMDA receptor. Patients present with psychiatric changes, epilepsy, motor, speech, or autonomic dysfunction, as well as decreased levels of consciousness. The diagnosis is made by collecting anti-NMDA receptor antibodies from the patient's cerebrospinal fluid. This disease provides an excellent example of the ubiquity of NMDA receptors. When attacked by an autoimmune disease, dysfunction in numerous neurologic functions occurs. Treatment commonly involves steroids, intravenous immunoglobulin, and plasma exchange therapy. Anti-NMDA receptor encephalitis is often&#x000a0;associated with ovarian teratomas.<xref ref-type="bibr" rid="article-25906.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Heavy metal poisoning:</italic> Evidence suggests that in heavy metal poisoning, metals such as lead bind to NMDA receptors and may exert some of their toxic effects there.<xref ref-type="bibr" rid="article-25906.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Migraines:&#x000a0;</italic>Magnesium is a treatment for migraines, and&#x000a0;NMDA receptors may be involved in their pathogenesis.<xref ref-type="bibr" rid="article-25906.r18">[18]</xref><xref ref-type="bibr" rid="article-25906.r19">[19]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25906.s7" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Aside from their involvement in many disease pathophysiologies, NMDA receptors are the pharmacologic target of both therapeutic drugs and drugs of abuse. Several examples of these include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Ketamine: </italic>An NMDA antagonist, it is used as a sedative, anesthetic, off-label as an antidepressant, or recreationally as a hallucinogenic drug of abuse.<xref ref-type="bibr" rid="article-25906.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Phencyclidine:</italic>&#x000a0;An NMDA antagonist. It is used recreationally as a hallucinogenic, depersonalizing, euphoric drug of abuse. It reportedly causes homicidal and suicidal impulses in users. Users characteristically experience nystagmus on physical exams.<xref ref-type="bibr" rid="article-25906.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Ethanol:</italic> A common recreational drug, it modulates NMDA receptors through complex mechanisms.<xref ref-type="bibr" rid="article-25906.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Memantine:</italic>&#x000a0;An uncompetitive NMDA antagonist, this drug is used in the treatment of Alzheimer disease and off-label for Huntington disease.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Amantadine:</italic> An NMDA antagonist used in the treatment of Parkinson disease and off-label for Huntington disease.<xref ref-type="bibr" rid="article-25906.r23">[23]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Magnesium: </italic>This naturally occurs in the transmembrane ion channel of the NMDA receptor. It&#x000a0;is used to prevent migraines and abort migraine aura, prevent seizures in preeclampsia, and as a neuroprotective agent administered to mothers of premature infants to prevent neonatal brain damage.<xref ref-type="bibr" rid="article-25906.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Methadone:&#x000a0;</italic>A mu-opioid agonist and NMDA antagonist used in the treatment of opioid addiction.<xref ref-type="bibr" rid="article-25906.r25">[25]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25906.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25906&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25906">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25906/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25906">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25906.s9">
        <title>References</title>
        <ref id="article-25906.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Willard</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Koochekpour</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Glutamate, glutamate receptors, and downstream signaling pathways.</article-title>
            <source>Int J Biol Sci</source>
            <year>2013</year>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>948</fpage>
            <page-range>948-59</page-range>
            <pub-id pub-id-type="pmid">24155668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vyklicky</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Korinek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Smejkalova</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Balik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krausova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaniakova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lichnerova</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cerny</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krusek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dittert</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Horak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vyklicky</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Structure, function, and pharmacology of NMDA receptor channels.</article-title>
            <source>Physiol Res</source>
            <year>2014</year>
            <volume>63</volume>
            <issue>Suppl 1</issue>
            <fpage>S191</fpage>
            <page-range>S191-203</page-range>
            <pub-id pub-id-type="pmid">24564659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kandel</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Dudai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mayford</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>The molecular and systems biology of memory.</article-title>
            <source>Cell</source>
            <year>2014</year>
            <month>Mar</month>
            <day>27</day>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>163</fpage>
            <page-range>163-86</page-range>
            <pub-id pub-id-type="pmid">24679534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ewald</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Cline</surname>
                <given-names>HT</given-names>
              </name>
            </person-group>
            <chapter-title>NMDA Receptors and Brain Development</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Van Dongen</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <source>Biology of the NMDA Receptor</source>
            <publisher-name>CRC Press/Taylor &#x00026; Francis</publisher-name>
            <publisher-loc>Boca Raton (FL)</publisher-loc>
            <year>2009</year>
            <pub-id pub-id-type="pmid">21204419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conti</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Localization of NMDA receptors in the cerebral cortex: a schematic overview.</article-title>
            <source>Braz J Med Biol Res</source>
            <year>1997</year>
            <month>May</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>555</fpage>
            <page-range>555-60</page-range>
            <pub-id pub-id-type="pmid">9283622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McRoberts</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Coutinho</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Marviz&#x000f3;n</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Grady</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Tognetto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sengupta</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Ennes</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Chaban</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Amadesi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Creminon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lanthorn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Geppetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bunnett</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats.</article-title>
            <source>Gastroenterology</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>120</volume>
            <issue>7</issue>
            <fpage>1737</fpage>
            <page-range>1737-48</page-range>
            <pub-id pub-id-type="pmid">11375955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Travis</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Verlander</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Zea</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Silverstein</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Expression and developmental regulation of the NMDA receptor subunits in the kidney and cardiovascular system.</article-title>
            <source>Am J Physiol Regul Integr Comp Physiol</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>283</volume>
            <issue>4</issue>
            <fpage>R964</fpage>
            <page-range>R964-71</page-range>
            <pub-id pub-id-type="pmid">12228067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r8">
          <label>8</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rezvani</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <chapter-title>Involvement of the NMDA System in Learning and Memory</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Levin</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Buccafusco</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <source>Animal Models of Cognitive Impairment</source>
            <publisher-name>CRC Press/Taylor &#x00026; Francis</publisher-name>
            <publisher-loc>Boca Raton (FL)</publisher-loc>
            <year>2006</year>
            <pub-id pub-id-type="pmid">21204373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mota</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>IL</given-names>
              </name>
              <name>
                <surname>Rego</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors.</article-title>
            <source>Neuropharmacology</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>76 Pt A</volume>
            <fpage>16</fpage>
            <page-range>16-26</page-range>
            <pub-id pub-id-type="pmid">23973316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ramsden</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Huntington's disease.</article-title>
            <source>Mol Pathol</source>
            <year>2001</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>6</issue>
            <fpage>409</fpage>
            <page-range>409-13</page-range>
            <pub-id pub-id-type="pmid">11724916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ondo</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Mejia</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>A pilot study of the clinical efficacy and safety of memantine for Huntington's disease.</article-title>
            <source>Parkinsonism Relat Disord</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>453</fpage>
            <page-range>453-4</page-range>
            <pub-id pub-id-type="pmid">17046312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verhagen Metman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Farmer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mosby</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wuu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chase</surname>
                <given-names>TN</given-names>
              </name>
            </person-group>
            <article-title>Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.</article-title>
            <source>Neurology</source>
            <year>2002</year>
            <month>Sep</month>
            <day>10</day>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>694</fpage>
            <page-range>694-9</page-range>
            <pub-id pub-id-type="pmid">12221159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Sheng</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>NMDA receptors in nervous system diseases.</article-title>
            <source>Neuropharmacology</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>74</volume>
            <fpage>69</fpage>
            <page-range>69-75</page-range>
            <pub-id pub-id-type="pmid">23583930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ramos-Quiroga</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Martin-Santos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Calvo-S&#x000e1;nchez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez-Rojas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meana</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.</article-title>
            <source>CNS Drugs</source>
            <year>2018</year>
            <month>May</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>411</fpage>
            <page-range>411-420</page-range>
            <pub-id pub-id-type="pmid">29736744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nore&#x000f1;a</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Revisiting the cochlear and central mechanisms of tinnitus and therapeutic approaches.</article-title>
            <source>Audiol Neurootol</source>
            <year>2015</year>
            <volume>20 Suppl 1</volume>
            <fpage>53</fpage>
            <page-range>53-9</page-range>
            <pub-id pub-id-type="pmid">25997584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Anti-N-Methyl-D-aspartate Receptor Encephalitis: A Severe, Potentially Reversible Autoimmune Encephalitis.</article-title>
            <source>Mediators Inflamm</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>6361479</fpage>
            <pub-id pub-id-type="pmid">28698711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Schuhmacher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Heavy metals (Pb, Cd, As and MeHg) as risk factors for cognitive dysfunction: A general review of metal mixture mechanism in brain.</article-title>
            <source>Environ Toxicol Pharmacol</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>48</volume>
            <fpage>203</fpage>
            <page-range>203-213</page-range>
            <pub-id pub-id-type="pmid">27816841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lauritzen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of the migraine aura. The spreading depression theory.</article-title>
            <source>Brain</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>117 ( Pt 1)</volume>
            <fpage>199</fpage>
            <page-range>199-210</page-range>
            <pub-id pub-id-type="pmid">7908596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bigal</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bordini</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Speciali</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study.</article-title>
            <source>Cephalalgia</source>
            <year>2002</year>
            <month>Jun</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>345</fpage>
            <page-range>345-53</page-range>
            <pub-id pub-id-type="pmid">12110110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdallah</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Sanacora</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Duman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Krystal</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?</article-title>
            <source>Pharmacol Ther</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>190</volume>
            <fpage>148</fpage>
            <page-range>148-158</page-range>
            <pub-id pub-id-type="pmid">29803629</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bertron</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Seto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lindsley</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>DARK Classics in Chemical Neuroscience: Phencyclidine (PCP).</article-title>
            <source>ACS Chem Neurosci</source>
            <year>2018</year>
            <month>Oct</month>
            <day>17</day>
            <volume>9</volume>
            <issue>10</issue>
            <fpage>2459</fpage>
            <page-range>2459-2474</page-range>
            <pub-id pub-id-type="pmid">29953199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ticku</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Regulation of NMDA receptors by ethanol.</article-title>
            <source>Prog Drug Res</source>
            <year>2000</year>
            <volume>54</volume>
            <fpage>152</fpage>
            <page-range>152-89</page-range>
            <pub-id pub-id-type="pmid">10857388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raupp-Barcaro</surname>
                <given-names>IF</given-names>
              </name>
              <name>
                <surname>Vital</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Galdur&#x000f3;z</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Andreatini</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials.</article-title>
            <source>Braz J Psychiatry</source>
            <year>2018</year>
            <season>Oct-Dec</season>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>449</fpage>
            <page-range>449-458</page-range>
            <pub-id pub-id-type="pmid">29898194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Connolly</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Worthley</surname>
                <given-names>LI</given-names>
              </name>
            </person-group>
            <article-title>Intravenous magnesium.</article-title>
            <source>Crit Care Resusc</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>1</volume>
            <issue>2</issue>
            <fpage>162</fpage>
            <page-range>162-72</page-range>
            <pub-id pub-id-type="pmid">16602999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25906.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aiyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gungor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gulati</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review of NMDA Receptor Antagonists for Treatment of Neuropathic Pain in Clinical Practice.</article-title>
            <source>Clin J Pain</source>
            <year>2018</year>
            <month>May</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>450</fpage>
            <page-range>450-467</page-range>
            <pub-id pub-id-type="pmid">28877137</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
